MannKind management will host a conference call to discuss these
results today at 5:00 p.m. Eastern Time. To participate in the call please
dial (888) 677-5721 or (210) 839-8507. To listen to the call via the
Internet please visit http://www.mannkindcorp.com. The web site replay will
be available for fourteen days. A telephone replay will be accessible for
approximately 14 days following completion of the call by dialing (800)
219-6350 or (402) 220-3904 and entering conference number 4423748.
Presenting from the Company will be:
-- Chairman and Chief Executive Officer Alfred Mann
-- President and Chief Operating Officer Hakan Edstrom
-- Corporate Vice President and Chief Financial Officer Matthew Pfeffer
-- Corporate Vice President and Chief Scientific Officer Peter Richardson
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its lead product, the Technosphere Insulin System, is currently in Phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit http://www.mannkindcorp.com.
This press release contains forward-looking statements, including
statements related to MannKind's expected G&A expenses, clinical trials,
|SOURCE MannKind Corporation|
Copyright©2008 PR Newswire.
All rights reserved